What question did this study set out to answer?

To assess the long-term outcomes of ischemic and hemorrhagic strokes in patients who discontinue oral anticoagulation after successful atrial fibrillation ablation.

June 27, 2026EP EuropaceOpen Access

Discontinuation of oral anticoagulation after successful atrial fibrillation treatment with radiofrequency and pulsed-field ablation

Q: What is the clinical evidence from this study?

Study design: Cohort. Population: Atrial fibrillation (n=333). Intervention: Discontinuation of oral anticoagulation vs. Continuation of oral anticoagulation. Primary outcome: Ischemic thromboembolic events (HR 0.46, 95% CI 0.18-1.23, p=0.113).

View Full Paper

Ask AI

Bookmark

Why the study?

Does discontinuation of oral anticoagulation after successful atrial fibrillation ablation increase the risk of thromboembolic events in high-risk patients?

Population

333 patients with atrial fibrillation and a CHA2DS2-VA score ≥ 2 who underwent successful catheter ablation…

Comparison

Discontinuation of oral anticoagulation therapy… vs Continuation of oral anticoagulation (OAC) therapy

Design

Cohort

Follow-up

median 4.9 years

Key result

Discontinuing oral anticoagulation after successful atrial fibrillation ablation did not significantly change ischemic thromboembolic event risk versus continuation (HR 0.46; 95% CI 0.18-1.23; p=0.113).

Authors

PCP China FVF Vacirca LQL Quinto

Discussion

Member takes

Overview

No significant thromboembolic difference observed; hypothesis-generating and leaves open need for randomized confirmation.

Key Points

To assess the long-term outcomes of ischemic and hemorrhagic strokes in patients who discontinue oral anticoagulation after successful atrial fibrillation ablation.
Included patients with CHA2DS2-VA score ≥ 2 undergoing ablation from 2010 to 2024.
Evaluated outcomes in OAC-OFF (discontinued) vs. OAC-ON (continued) groups.
Follow-up lasted a minimum of 12 months post-ablation.
No significant difference in ischemic thromboembolic events between groups (p=0.113; HR 0.46, 95% CI 0.18–1.23).
Hemorrhagic strokes occurred only in the OAC-ON group; major bleeding was twice as frequent in this group but not statistically significant (p=0.314).
Composite endpoint of events or all-cause death was higher in the OAC-ON group, but no significant difference was found in adjusted analysis.

Study Design

Type

Cohort (n=333)

Multicenter

Structured PICO

Does discontinuation of oral anticoagulation after successful atrial fibrillation ablation increase the risk of thromboembolic events in high-risk patients?

Population

333 patients with atrial fibrillation and a CHA2DS2-VA score ≥ 2 who underwent catheter ablation, followed for a median of 4.9 years.

Exposure

Discontinuation of oral anticoagulation (OAC) therapy during follow-up based on physician assessment

Comparator

Continuation of oral anticoagulation (OAC) therapy

Outcome

Long-term incidence of ischemic and hemorrhagic stroke, systemic thromboembolic events, and bleedingshard clinical

Main Result

Hazard Ratio: 0.46 (95% CI 0.18–1.23)

p-value: p=0.113

Discontinuation of oral anticoagulation after successful atrial fibrillation ablation in high-risk patients appears safe and does not significantly increase the risk of ischemic thromboembolic events compared to continuation.

Cite This Study

China et al. (2026) conducted a cohort in Atrial fibrillation (n=333). Discontinuation of oral anticoagulation vs. Continuation of oral anticoagulation was evaluated on Ischemic thromboembolic events (HR 0.46, 95% CI 0.18-1.23, p=0.113). Discontinuing oral anticoagulation after successful atrial fibrillation ablation did not significantly change ischemic thromboembolic event risk versus continuation (HR 0.46; 95% CI 0.18-1.23; p=0.113).

synapsesocial.com/papers/6a3f97e8125782b61d865af4 https://doi.org/10.1093/europace/euag105.403

View Full Paper

Ask AI

Bookmark

June 27, 2026EP EuropaceOpen Access

Discontinuation of oral anticoagulation after successful atrial fibrillation treatment with radiofrequency and pulsed-field ablation

View Full Paper

Ask AI

Bookmark

Why the study?

Does discontinuation of oral anticoagulation after successful atrial fibrillation ablation increase the risk of thromboembolic events in high-risk patients?

Population

333 patients with atrial fibrillation and a CHA2DS2-VA score ≥ 2 who underwent successful catheter ablation…

Comparison

Discontinuation of oral anticoagulation therapy… vs Continuation of oral anticoagulation (OAC) therapy

Design

Cohort

Follow-up

median 4.9 years

Key result

Authors

PCP China FVF Vacirca LQL Quinto

Discussion

Member takes

Overview

No significant thromboembolic difference observed; hypothesis-generating and leaves open need for randomized confirmation.

Key Points

To assess the long-term outcomes of ischemic and hemorrhagic strokes in patients who discontinue oral anticoagulation after successful atrial fibrillation ablation.
Included patients with CHA2DS2-VA score ≥ 2 undergoing ablation from 2010 to 2024.
Evaluated outcomes in OAC-OFF (discontinued) vs. OAC-ON (continued) groups.
Follow-up lasted a minimum of 12 months post-ablation.
No significant difference in ischemic thromboembolic events between groups (p=0.113; HR 0.46, 95% CI 0.18–1.23).
Hemorrhagic strokes occurred only in the OAC-ON group; major bleeding was twice as frequent in this group but not statistically significant (p=0.314).
Composite endpoint of events or all-cause death was higher in the OAC-ON group, but no significant difference was found in adjusted analysis.

Study Design

Type

Cohort (n=333)

Multicenter

Structured PICO

Does discontinuation of oral anticoagulation after successful atrial fibrillation ablation increase the risk of thromboembolic events in high-risk patients?

Population

333 patients with atrial fibrillation and a CHA2DS2-VA score ≥ 2 who underwent catheter ablation, followed for a median of 4.9 years.

Exposure

Discontinuation of oral anticoagulation (OAC) therapy during follow-up based on physician assessment

Comparator

Continuation of oral anticoagulation (OAC) therapy

Outcome

Long-term incidence of ischemic and hemorrhagic stroke, systemic thromboembolic events, and bleedingshard clinical

Main Result

Hazard Ratio: 0.46 (95% CI 0.18–1.23)

p-value: p=0.113

Cite This Study

synapsesocial.com/papers/6a3f97e8125782b61d865af4 https://doi.org/10.1093/europace/euag105.403

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark